US20070009921A1 - Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances - Google Patents

Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances Download PDF

Info

Publication number
US20070009921A1
US20070009921A1 US11/316,467 US31646705A US2007009921A1 US 20070009921 A1 US20070009921 A1 US 20070009921A1 US 31646705 A US31646705 A US 31646705A US 2007009921 A1 US2007009921 A1 US 2007009921A1
Authority
US
United States
Prior art keywords
amino acid
acid sequence
peptide
virus
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/316,467
Inventor
Jurgen Walter
Christian Reiser
Wolf Bertling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
responsif GmbH
Original Assignee
responsif GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by responsif GmbH filed Critical responsif GmbH
Priority to US11/316,467 priority Critical patent/US20070009921A1/en
Publication of US20070009921A1 publication Critical patent/US20070009921A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to a synthetic biologically active molecule and to a method for the preparation thereof.
  • U.S. Pat. No. 4,950,599 discloses that the polyoma virus is suitable for transporting active substances into cells. Furthermore, DE 196 18 797 A1 discloses that a capsomer derived from polyoma virus is suited to transporting molecular material into cells.
  • EP 0 259 149 A2 discloses using the rotavirus internal capsid protein VP6 as immunological carrier molecule and as a vaccine for stimulating the immune response to rotavirus infections.
  • immunogenic peptides are bound to VP6 via peptide-peptide interactions which are not defined in any detail.
  • VP6 here does not form a structural capsomer but on the contrary displays a distinctive structural polymorphism.
  • VP6 is present as a monomer or in oligomeric form. Although oligomeric VP6 can form particles, these particles are not capsids or capsomers but unstructured carrier proteins.
  • Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins
  • Mol. Immunol. 28, 269-278 describe the use of rotavirus internal capsid protein VP6 as transport particle.
  • VP6 is bound to immunogenic peptides or proteins via a binding protein derived from the peptide sequence of the rotaviral protein VP4.
  • An antigen coupled to the peptide sequence derived from VP4 is located on the outside of the transport particle and therefore is not protected from degradation.
  • GB 22 57 431 A describes the use of a chimeric protein which is derived from the envelope protein of phage MS-2. This protein can form capsids. Antigenic peptides or the like coupled thereto are bound to the outside of the capsid. Spontaneous assembling of the chimeric protein during expression in E. coli carries a high risk of contamination by bacterial DNA or proteins.
  • DE 43 35 025 A1 discloses an endosomolytically active virus-like particle which has been modified with membrane-active peptides on its outer surface. The preparation of said particle is complicated.
  • Derived amino acid sequence amino acid sequence which is unchanged compared with the amino acid sequence from which it is derived, or which differs therefrom by amino acid exchanges, insertions or deletions.
  • C-terminal end region or area at the C terminals.
  • Synthetic molecule artificially prepared molecule.
  • Coupling or attaching covalent or noncovalent binding.
  • Noncovalent binding may be carried out, for example, via a chelate bond.
  • Genetic engineering technique which includes methods for introducing defined nucleic acids into cells.
  • a synthetic biologically active molecule wherein an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus is linked to an active substance.
  • A1 amino acid sequence derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus is linked to an active substance.
  • the proposed synthetic biologically active molecule makes it possible in a simple manner to specifically associate active substances with polyoma virus VP1. This leads to the formation of a structured capsomer. By using said capsomer it is possible to prepare in a simple manner capsids as universal carriers for active substances.
  • the amino acid sequence (A1) comprises from 10 to 55, preferably from 28 to 38, amino acids. Limitation to a relatively short amino acid sequence reduces the cost of and simplifies the preparation of the synthetic biologically active molecule.
  • the amino acid sequence at least in some sections corresponds to the VP2 sequence from amino acid position 250 to 319, preferably from amino acid position 260 to 300 and particularly preferably from amino acid position 287 to 297. Said amino acid sequence ensures secure anchoring to VP1.
  • amino acid sequence (A1) preferably has amino acids in the sequence below: Trp Met Leu Pro Leu Ile Leu Gly Leu Tyr Gly 1 5 10
  • the active substance is preferably bound to the amino acid sequence (A1) via a linker.
  • This linker may be composed of at least one amino acid, a peptide, protein, lipid or the like.
  • the active substance may be selected from the following group: nucleic acid, oligonucleotide, protein, peptide, peptidic substance, PNA, modifications of said substances and low-molecular weight pharmaceutically active substances. Particularly suitable are those active substances which couple to the amino acid sequence via one of the reactive groups mentioned below.
  • the synthetic biologically active molecule may be present coupled to an amino acid sequence derived from polyoma virus VP1 and/or may be an ingredient of a medicament.
  • amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus, with the amino acid sequence (A1) having a coupling agent and
  • the coupling agent may have as amino acid glycine, cysteine or glycine bound via lysine.
  • the coupling agent is advantageously a further, preferably synthetically prepared amino acid sequence (A2) bound to the N- or C-terminal end of amino acid sequence (A1).
  • the synthetic biologically active molecule may be prepared, at least partly, by genetic engineering.
  • the amino acid sequence (A1), the further amino acid sequence (A2) and the active substance may be prepared completely or partially by genetic engineering.
  • the further amino acid sequence (A2) expediently has glycines and/or amino acids with functional side groups, it being possible for the functional side groups to be selected from the following group: amino, sulfhydryl, carboxyl, hydroxyl, guanidinium, phenyl, indole and imidazole radical.
  • the coupling agent may be a reactive group bound to the C- or N-terminal end of amino acid sequence (A1) via an amino acid, preferably glycine, cysteine, or glycine bound via lysine.
  • This may have one of the following components: amino acid with monobrqmoacetyl radical, amino acid with monochloroacetyl radical, amino acid with 3-nitro-2-pyridinesulfenyl radical (Npys).
  • the proposed reactive groups can be used universally. They are suitable for coupling to a multiplicity of active substances.
  • the active substance may be bound to amino acid sequence (A1) or the further amino acid sequence (A2) via a linker.
  • the linker may be composed of at least one amino acid, a peptide, protein, lipid, or the like.
  • aa synthesizing an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus and
  • steps under aa and under bb are carried out by means of peptide synthesis or by means of genetic engineering methods.
  • step bb) the amino acid sequence (A1) is extended by the active substance.
  • the elongation and the attaching of the active substance are carried out by repeatedly attaching amino acid residues. This method can be carried out particularly easily.
  • Peptides are synthesized by simultaneous multiple peptides synthesis (Schnorrenberg, G. and Gerhardt, H. (1989) Tetrahedron 45, 7759) in a peptide synthesizer (type: PSSM-8 from SHIMADZU, Japan) using the 9-fluorenylmethoxycarbonyl (Fmoc)/tert. butyl (But) strategy according to Sheppard (Atherton, E. and Sheppard, R. C. (1989) “Solid phase peptide synthesis—a practical approach” IRL Press, Oxford).
  • the coupling reactions are carried out with in each case 6 equivalents of Fmoc-protected amino acid/1-hydroxybenzotriazole (HOBt)/12 equivalents of n-methylmorpholine using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) on a polymeric carrier resin (type: Tentagel S Trityl resin, RAPP Polymere, Tubingen, Germany) with a load of 2 mmol/g of resin.
  • the peptides contain a C-terminal COOH group.
  • the peptides are purified by means of preparative HPLC on a Bischoff Polyencap 300 separating column, 10 ⁇ m, 250 ⁇ 16 mm, using a gradient of from 0.05% trifluoroacetic acid in water (eluent A) to 0.05% trifluoroacetic acid in 80% acetonitrile/water (eluent B).
  • Vydac separating column of type 218 TP 101522 (10-15 ⁇ m, 250 ⁇ 22 mm) with a gradient of 43-73% eluent B in 30 min at a flow rate of 15 ml/min was used.
  • the reactive group is bound to the N-terminal end of the amino acid sequence via an amino acid, preferably via glycine.
  • the reactive group may be composed of monochloroacetylglycine. Alternatively, it is also possible to attach a monobromoacetyl radical.
  • the reactive group facilitates covalent binding of the biologically active molecule prepared in this way to an active substance, for example a peptide, which has a free SH group.
  • an active substance for example a peptide, which has a free SH group.
  • the reaction of the SH group with the chlorine atom of the monochloroacetyl group results in the formation of a stable thioether compound according to the following equation: Conjugate Formation Between a monochloroacetyl-Modified Anchor Peptide and a Peptide Having a Terminal Cysteine:
  • a monochloroacetyl-modified anchor peptide is used in excess of the peptide to be conjugated.
  • the reaction is carried out in 0.1 M NaHCO 3 between [sic] pH 7-8 at room temperature.
  • the conjugate formation is carried out in 4 M guanidine hydrochloride, pH 8.0 (Lindner, W. and Robey, F. A. (1987) Int. J. Pept. Protein Res. 30, 794-800).
  • the proportion of organic solvent, for example DMSO in the reaction mixture can be increased.
  • water-soluble phosphines may be added as reducing agent.
  • the conjugation reaction may also be carried out as follows.
  • the peptide containing the SH group is dissolved in 0.2 M phosphate buffer, 10 mM EDTA, pH 7.4.
  • the monochloroacetyl-modified anchor peptide dissolved in dimethylformamide is added.
  • purification is carried out by gel filtration or RP-HPLC (Zhang, L. and Tam, J. P. (1997) J. Am. Chem. Soc. 119, 2363-2370).
  • the protein is purified via Ni-NTA affinity chromatography.
  • the His tag is removed by treatment with a factor Xa.
  • the protein is analyzed in an SDS-PAGE gel with subsequent Coomassie staining.
  • This starting material (VP1 protein in 20 mM Hepes, pH 7.3, 1 mM EDTA, 200 mN NaCl, 5% glycerol) is concentrated in a centricon 100 (Amincon [sic]) and separated via FPLC gel filtration (Superdex 200) with an elution buffer (50 mM Tris, 0.15 M NaCl, 5 mM EDTA, pH 8.5) into the high-molecular weight capsid fraction and the pentamer subunits (molecular weight: about 225 kD). Both fractions are concentrated in centricon 100.
  • Iodoacetamide (SIGMA) is added to the pentamer-containing solution in a 10-fold molar excess, in order to block potentially reactive SH groups. The reaction is carried out at room temperature for 2 hours.
  • the modified pentamer fraction is separated from excess iodoacetamide via gel filtration.
  • VP1-specific monoclonal antibodies are adsorbed with the aid of VP1-specific antibodies and an affinity matrix (protein A support from BIO-RAD).
  • the antibody-coated matrix is used to precipitate the purified pentamer fraction.
  • the anchor sequence is added to the pentamer matrix.
  • the samples are analyzed in an SDS polyacrylamide gel (12.5%).
  • Npys 3-nitro-2-pyridinesulfenyl
  • Said Npys-modified cysteine is an “activated disulfide” which is capable of reacting with thiols such as, for example, cysteines, to form an unsymmetric disulfide. This results in the removal of 3-nitro-2-thiopyridone whose UV maximum at 329 nm permits studying the kinetics of the reaction between the two compounds by spectrometry.
  • the following conditions are chosen for the reaction (Albericio, F., Andreu, D., Giralt, E., Navalpotro, C., Pedroso, E., Ponsati, B. and Ruiz-Gayo, M. (1989) Int. J. Peptide Res. 34, 124-128).
  • the Npys-modified peptide is added to the peptide to be coupled having a terminal SH group and dissolved in 0.1 M sodium acetate, 0.1 M sodium chloride, pH 4.5, and the pH is then adjusted to 5.0 followed by incubation with stirring for at least 12 h. The pH is then adjusted to 7.0 by adding 1 N NaOH followed by another incubation for 3 h.
  • the optimal pH range of the reaction is between 4.5 and 7.0. These conditions ensure minimization of unwanted side reactions such as, for example, formation of symmetric disulfides between the peptide molecules to be coupled or removal of the Npys group.
  • the Npys-modified peptide should be present in the reaction in excess over the peptide to be conjugated (Albericio, F., Andreu, D., Giralt, E., Navalpotro, C., Pedroso, E., Ponsati, B. and Ruiz-Gayo, M. (1989) Int. J. Peptide Res. 34, 124-128).
  • Sequence listing 1 depicts an amino acid sequence derived from polyoma virus VP2, position 287-297. It serves in the synthetic biologically active molecule as anchor for anchoring the active substance to VP1.
  • Sequence listing 2 depicts a first exemplary embodiment of a synthetic biologically active molecule.
  • the HIV-1-derived peptide sequence corresponds to positions 1-21; the attached amino acid sequence acting as anchor occupies positions 22-33. It is derived from polyoma virus VP2.
  • Sequence listing 3 depicts another example of an amino acid sequence suitable as anchor.
  • Sequence listing 4 depicts the polyoma virus VP2 sequence. This shows the sequences between positions 250 and 300, which are suitable as anchors.
  • Sequence listings 5 and 6 show further synthetic biologically active molecules. They may be coupled with polyoma virus VP1 and then, for treatment of an HIV infection, be introduced into the infected cells.

Abstract

The invention relates to a synthetic, biologically active molecule for fixing an active ingredient to the virus protein 1 (VP1) of the polyoma virus. According to the invention, an amino acid sequence A1 which is derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of the polyoma virus is bonded to an active ingredient at one of its ends.

Description

  • The invention relates to a synthetic biologically active molecule and to a method for the preparation thereof.
  • Chen, X. S., Stehle, T. and Harrison, S. C. (1998): Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry, The EMBO Journal, Vol. 17, No. 12, pp. 3233-3240 describe the interactions responsible for anchoring virus proteins VP2 and VP3 of polyoma virus to virus protein 1. According to said publication, the anchoring takes place in the region of the C-terminal end of VP2 or VP3.
  • U.S. Pat. No. 4,950,599 discloses that the polyoma virus is suitable for transporting active substances into cells. Furthermore, DE 196 18 797 A1 discloses that a capsomer derived from polyoma virus is suited to transporting molecular material into cells.
  • EP 0 259 149 A2 discloses using the rotavirus internal capsid protein VP6 as immunological carrier molecule and as a vaccine for stimulating the immune response to rotavirus infections. In this connection, immunogenic peptides are bound to VP6 via peptide-peptide interactions which are not defined in any detail. VP6 here does not form a structural capsomer but on the contrary displays a distinctive structural polymorphism. VP6 is present as a monomer or in oligomeric form. Although oligomeric VP6 can form particles, these particles are not capsids or capsomers but unstructured carrier proteins.
  • Redmond, M. J. et al. (1991): Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins, Mol. Immunol. 28, 269-278 describe the use of rotavirus internal capsid protein VP6 as transport particle. In this connection, VP6 is bound to immunogenic peptides or proteins via a binding protein derived from the peptide sequence of the rotaviral protein VP4. An antigen coupled to the peptide sequence derived from VP4 is located on the outside of the transport particle and therefore is not protected from degradation.
  • GB 22 57 431 A describes the use of a chimeric protein which is derived from the envelope protein of phage MS-2. This protein can form capsids. Antigenic peptides or the like coupled thereto are bound to the outside of the capsid. Spontaneous assembling of the chimeric protein during expression in E. coli carries a high risk of contamination by bacterial DNA or proteins.
  • DE 43 35 025 A1 discloses an endosomolytically active virus-like particle which has been modified with membrane-active peptides on its outer surface. The preparation of said particle is complicated.
  • It is the object of the invention to remove the disadvantages according to the prior art. In particular it is intended to provide a simple possibility of specifically associating active substances with polyoma virus VP1.
  • This object is achieved by the features of claims 1, 9 and 19. Expedient embodiments result from the features of claims 2 to 8, 10 to 18 and 20 to 24.
  • The description makes use of the following definitions: Derived amino acid sequence: amino acid sequence which is unchanged compared with the amino acid sequence from which it is derived, or which differs therefrom by amino acid exchanges, insertions or deletions.
  • C-terminal end: region or area at the C terminals.
  • Synthetic molecule: artificially prepared molecule.
  • Coupling or attaching: covalent or noncovalent binding. Noncovalent binding may be carried out, for example, via a chelate bond.
  • Genetic engineering: technique which includes methods for introducing defined nucleic acids into cells.
  • In accordance with the invention, a synthetic biologically active molecule is provided for, wherein an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus is linked to an active substance.
  • The proposed synthetic biologically active molecule makes it possible in a simple manner to specifically associate active substances with polyoma virus VP1. This leads to the formation of a structured capsomer. By using said capsomer it is possible to prepare in a simple manner capsids as universal carriers for active substances.
  • Advantageously, the amino acid sequence (A1) comprises from 10 to 55, preferably from 28 to 38, amino acids. Limitation to a relatively short amino acid sequence reduces the cost of and simplifies the preparation of the synthetic biologically active molecule.
  • Expediently, the amino acid sequence at least in some sections corresponds to the VP2 sequence from amino acid position 250 to 319, preferably from amino acid position 260 to 300 and particularly preferably from amino acid position 287 to 297. Said amino acid sequence ensures secure anchoring to VP1.
  • In the synthetic biologically active molecule, the amino acid sequence (A1) preferably has amino acids in the sequence below:
    Trp Met Leu Pro Leu Ile Leu Gly Leu Tyr Gly
       1                5                  10
  • The active substance is preferably bound to the amino acid sequence (A1) via a linker. This linker may be composed of at least one amino acid, a peptide, protein, lipid or the like. The active substance may be selected from the following group: nucleic acid, oligonucleotide, protein, peptide, peptidic substance, PNA, modifications of said substances and low-molecular weight pharmaceutically active substances. Particularly suitable are those active substances which couple to the amino acid sequence via one of the reactive groups mentioned below.
  • The synthetic biologically active molecule may be present coupled to an amino acid sequence derived from polyoma virus VP1 and/or may be an ingredient of a medicament.
  • In further accordance with the invention, a method for preparing the synthetic biologically active molecule of the invention is provided for, which method has the following steps:
  • a) providing an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus, with the amino acid sequence (A1) having a coupling agent and
  • b) binding the active substance to the amino acid sequence (A1) via the coupling agent.
  • The coupling agent may have as amino acid glycine, cysteine or glycine bound via lysine. The coupling agent is advantageously a further, preferably synthetically prepared amino acid sequence (A2) bound to the N- or C-terminal end of amino acid sequence (A1).
  • The synthetic biologically active molecule may be prepared, at least partly, by genetic engineering. In this connection, the amino acid sequence (A1), the further amino acid sequence (A2) and the active substance may be prepared completely or partially by genetic engineering. The further amino acid sequence (A2) expediently has glycines and/or amino acids with functional side groups, it being possible for the functional side groups to be selected from the following group: amino, sulfhydryl, carboxyl, hydroxyl, guanidinium, phenyl, indole and imidazole radical.
  • The coupling agent may be a reactive group bound to the C- or N-terminal end of amino acid sequence (A1) via an amino acid, preferably glycine, cysteine, or glycine bound via lysine. This may have one of the following components: amino acid with monobrqmoacetyl radical, amino acid with monochloroacetyl radical, amino acid with 3-nitro-2-pyridinesulfenyl radical (Npys). The proposed reactive groups can be used universally. They are suitable for coupling to a multiplicity of active substances.
  • It has proved particularly advantageous to bind the active substance to amino acid sequence (A1) or to the further amino acid sequence (A2) via a thioether or disulfide bridge. In practice, this kind of bond can readily be prepared. Of course, the use of other reactive groups is also conceivable. Suitable groups are, for example, N-succinimidyl bromoacetate or N-succinimidyl 3-(2-pyridylthio)propionate (SPDP).
  • The active substance may be bound to amino acid sequence (A1) or the further amino acid sequence (A2) via a linker. The linker may be composed of at least one amino acid, a peptide, protein, lipid, or the like.
  • In further accordance with the invention, a method for preparing the synthetic biologically active molecule of the invention is provided for, which method has the following steps:
  • aa) synthesizing an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus and
  • bb) coupling and synthesizing an active substance, namely a peptide, to the amino acid sequence (A1),
  • wherein the steps under aa and under bb are carried out by means of peptide synthesis or by means of genetic engineering methods.
  • In step bb) the amino acid sequence (A1) is extended by the active substance. The elongation and the attaching of the active substance are carried out by repeatedly attaching amino acid residues. This method can be carried out particularly easily.
  • Further advantageous embodiments relating to both aforementioned methods can be found in the subclaims.
    • EXAMPLES
  • A. Synthesis and Purification of the Peptides:
  • Peptides are synthesized by simultaneous multiple peptides synthesis (Schnorrenberg, G. and Gerhardt, H. (1989) Tetrahedron 45, 7759) in a peptide synthesizer (type: PSSM-8 from SHIMADZU, Japan) using the 9-fluorenylmethoxycarbonyl (Fmoc)/tert. butyl (But) strategy according to Sheppard (Atherton, E. and Sheppard, R. C. (1989) “Solid phase peptide synthesis—a practical approach” IRL Press, Oxford). The coupling reactions are carried out with in each case 6 equivalents of Fmoc-protected amino acid/1-hydroxybenzotriazole (HOBt)/12 equivalents of n-methylmorpholine using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) on a polymeric carrier resin (type: Tentagel S Trityl resin, RAPP Polymere, Tubingen, Germany) with a load of 2 mmol/g of resin. The peptides contain a C-terminal COOH group.
  • The following protective groups are used in the synthesis: Cys (Trt), Arg (Pbf), Ser (But), Thr (But), Asp (OBut), Glu, (OBut), Asn (Trt), Gln (Trt), Lys (Boc), His (Trt), Trp (Boc), where Trt: trityl, But: t-butyl, OBut: t-butyl ester, Boc: t-butyloxycarbonyl and Pbf: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.
  • All protective groups are removed using trifluoroacetic acid (TFA)/thioanisole/thiocresol (95:2.5:2.5) at room temperature over 3 h with the addition of 3% triisopropylsilane and subsequent addition of 10% trimethylchlorosilane for 1 h. After lyophilization, the peptides are present in the form of their trifluoroacetic acid salts.
  • The peptides are purified by means of preparative HPLC on a Bischoff Polyencap 300 separating column, 10 μm, 250×16 mm, using a gradient of from 0.05% trifluoroacetic acid in water (eluent A) to 0.05% trifluoroacetic acid in 80% acetonitrile/water (eluent B).
  • Alternatively, a Vydac separating column of type 218 TP 101522 (10-15 μm, 250×22 mm) with a gradient of 43-73% eluent B in 30 min at a flow rate of 15 ml/min was used.
  • By means of peptide synthesis, the following amino acid sequence is synthesized, for example:
    Trp Met Leu Pro Leu Ile Leu Gly Leu Tyr Gly
       1                5                  10
  • In this sequence, the reactive group is bound to the N-terminal end of the amino acid sequence via an amino acid, preferably via glycine. The reactive group may be composed of monochloroacetylglycine. Alternatively, it is also possible to attach a monobromoacetyl radical.
  • Coupling of monochloroacetylglycine in Solid Phase Synthesis:
  • Equal equivalents of monochloroacetylglycine and 1-hydroxybenzotriazole (HOBt) are dissolved in dimethylformamide (DMF) mixed with an equal equivalent of N,N′-diisopropylcarbodiimide (DIC) and added to the peptide resin. Compared with the loaded peptide resin, monochloroacetylglycine is present in excess. The reaction is carried out with occasional stirring and should last for at least 1 h.
  • The reactive group facilitates covalent binding of the biologically active molecule prepared in this way to an active substance, for example a peptide, which has a free SH group. The reaction of the SH group with the chlorine atom of the monochloroacetyl group results in the formation of a stable thioether compound according to the following equation:
    Figure US20070009921A1-20070111-C00001
    Conjugate Formation Between a monochloroacetyl-Modified Anchor Peptide and a Peptide Having a Terminal Cysteine:
  • A monochloroacetyl-modified anchor peptide is used in excess of the peptide to be conjugated. The reaction is carried out in 0.1 M NaHCO3 between [sic] pH 7-8 at room temperature. In the case of poor solubility of the peptide or the anchor in aqueous solution, the conjugate formation is carried out in 4 M guanidine hydrochloride, pH 8.0 (Lindner, W. and Robey, F. A. (1987) Int. J. Pept. Protein Res. 30, 794-800). Alternatively, the proportion of organic solvent, for example DMSO, in the reaction mixture can be increased. In order to avoid unwanted by-products, water-soluble phosphines may be added as reducing agent.
  • Optionally it is also possible to carry out the conjugation reaction under the following conditions. The monochloroacetylated anchor peptide and a peptide having a terminal SH group are incubated at room temperature in 1-methyl-2-pyrrolidone in the presence of about 10-fold excess of diisopropylethylamine and an approx. 5-fold excess of tributylphosphine. After the reaction, H2O is subsequently added and the product is precipitated by the addition of ether and purified by gel filtration (Defoort, J. P., Nardelli, B., Huang, W. and Tam, J. P. (1992) Int. J. Protein Res. 40, 214-221).
  • Optionally the conjugation reaction may also be carried out as follows. The peptide containing the SH group is dissolved in 0.2 M phosphate buffer, 10 mM EDTA, pH 7.4. To this mixture, the monochloroacetyl-modified anchor peptide dissolved in dimethylformamide is added. After the reaction, purification is carried out by gel filtration or RP-HPLC (Zhang, L. and Tam, J. P. (1997) J. Am. Chem. Soc. 119, 2363-2370).
  • Isolated VP1 pentamers are prepared by expressing VP1 as a recombinant protein with an N-terminal 6× histidine affinity tag (=His tag) in E. coli. The protein is purified via Ni-NTA affinity chromatography. The His tag is removed by treatment with a factor Xa. The protein is analyzed in an SDS-PAGE gel with subsequent Coomassie staining.
  • This starting material (VP1 protein in 20 mM Hepes, pH 7.3, 1 mM EDTA, 200 mN NaCl, 5% glycerol) is concentrated in a centricon 100 (Amincon [sic]) and separated via FPLC gel filtration (Superdex 200) with an elution buffer (50 mM Tris, 0.15 M NaCl, 5 mM EDTA, pH 8.5) into the high-molecular weight capsid fraction and the pentamer subunits (molecular weight: about 225 kD). Both fractions are concentrated in centricon 100. Iodoacetamide (SIGMA) is added to the pentamer-containing solution in a 10-fold molar excess, in order to block potentially reactive SH groups. The reaction is carried out at room temperature for 2 hours. The modified pentamer fraction is separated from excess iodoacetamide via gel filtration. VP1-specific monoclonal antibodies are adsorbed with the aid of VP1-specific antibodies and an affinity matrix (protein A support from BIO-RAD). The antibody-coated matrix is used to precipitate the purified pentamer fraction. In a further incubation step, the anchor sequence is added to the pentamer matrix. The samples are analyzed in an SDS polyacrylamide gel (12.5%).
  • Conjugate Formation Between an Npys-Modified Anchor Peptide and a Peptide having a Terminal Cysteine:
  • In addition to the reaction between a monochloro- or monobromoacetylated anchor peptide and a peptide having a terminal cysteine with formation of a thioether, the conjugate between anchor peptide and peptide sequence may optionally also be formed via the 3-nitro-2-pyridinesulfenyl (=Npys) group on a terminal cysteine of the anchor and an SH group of the peptide to be coupled. To this end, an Npys-modified cysteine instead of a monochloroacetylated glycine is coupled N-terminally to the anchor sequence. Said Npys-modified cysteine is an “activated disulfide” which is capable of reacting with thiols such as, for example, cysteines, to form an unsymmetric disulfide. This results in the removal of 3-nitro-2-thiopyridone whose UV maximum at 329 nm permits studying the kinetics of the reaction between the two compounds by spectrometry.
  • The following conditions are chosen for the reaction (Albericio, F., Andreu, D., Giralt, E., Navalpotro, C., Pedroso, E., Ponsati, B. and Ruiz-Gayo, M. (1989) Int. J. Peptide Res. 34, 124-128). The Npys-modified peptide is added to the peptide to be coupled having a terminal SH group and dissolved in 0.1 M sodium acetate, 0.1 M sodium chloride, pH 4.5, and the pH is then adjusted to 5.0 followed by incubation with stirring for at least 12 h. The pH is then adjusted to 7.0 by adding 1 N NaOH followed by another incubation for 3 h. After the reaction, the mixture is dialyzed against 10 mN NaHCO3. The optimal pH range of the reaction is between 4.5 and 7.0. These conditions ensure minimization of unwanted side reactions such as, for example, formation of symmetric disulfides between the peptide molecules to be coupled or removal of the Npys group. The Npys-modified peptide should be present in the reaction in excess over the peptide to be conjugated (Albericio, F., Andreu, D., Giralt, E., Navalpotro, C., Pedroso, E., Ponsati, B. and Ruiz-Gayo, M. (1989) Int. J. Peptide Res. 34, 124-128).
  • Examples of the invention are illustrated in the following sequence listings:
  • Sequence listing 1 depicts an amino acid sequence derived from polyoma virus VP2, position 287-297. It serves in the synthetic biologically active molecule as anchor for anchoring the active substance to VP1.
  • Sequence listing 2 depicts a first exemplary embodiment of a synthetic biologically active molecule. The HIV-1-derived peptide sequence corresponds to positions 1-21; the attached amino acid sequence acting as anchor occupies positions 22-33. It is derived from polyoma virus VP2.
  • Sequence listing 3 depicts another example of an amino acid sequence suitable as anchor.
  • Sequence listing 4 depicts the polyoma virus VP2 sequence. This shows the sequences between positions 250 and 300, which are suitable as anchors.
  • Sequence listings 5 and 6 show further synthetic biologically active molecules. They may be coupled with polyoma virus VP1 and then, for treatment of an HIV infection, be introduced into the infected cells.

Claims (1)

1. A synthetic biologically active molecule composed of an active substance and an amino acid sequence (A1) derived from the C-terminal end of virus protein 2 (VP2) or 3 (VP3) of polyoma virus, wherein the active substance is bound to the amino acid sequence (A1) so that the active substance can be associated with the virus protein 1 (VP1) of polyoma virus by means of the amino acid sequence (A1) with the formation of a structured capsomer, and wherein the amino acid sequence (A1) linked to the active substance is not VP2 or VP3.
US11/316,467 1999-04-10 2005-12-22 Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances Abandoned US20070009921A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/316,467 US20070009921A1 (en) 1999-04-10 2005-12-22 Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19916224A DE19916224C1 (en) 1999-04-10 1999-04-10 Synthetic molecule for delivering active ingredient to cell, used e.g. to treat human immune deficiency virus infection, comprises the ingredient linked to VP2 or 3 peptide from polyoma virus
DE19916224.7 1999-04-10
US09/958,451 US7011968B1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
PCT/DE2000/000976 WO2000061616A1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
US11/316,467 US20070009921A1 (en) 1999-04-10 2005-12-22 Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/958,451 Continuation US7011968B1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
PCT/DE2000/000976 Continuation WO2000061616A1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients

Publications (1)

Publication Number Publication Date
US20070009921A1 true US20070009921A1 (en) 2007-01-11

Family

ID=7904139

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/958,451 Expired - Fee Related US7011968B1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
US11/316,467 Abandoned US20070009921A1 (en) 1999-04-10 2005-12-22 Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/958,451 Expired - Fee Related US7011968B1 (en) 1999-04-10 2000-04-03 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients

Country Status (19)

Country Link
US (2) US7011968B1 (en)
EP (2) EP1173475B1 (en)
JP (1) JP2002544122A (en)
KR (1) KR100627935B1 (en)
CN (1) CN1346366A (en)
AT (1) ATE303401T1 (en)
AU (1) AU768669B2 (en)
BR (1) BR0011178A (en)
CA (1) CA2364536A1 (en)
CZ (1) CZ20013621A3 (en)
DE (3) DE19916224C1 (en)
EA (1) EA006631B1 (en)
HU (1) HUP0200679A2 (en)
IL (1) IL145403A0 (en)
MX (1) MXPA01010189A (en)
NO (1) NO20014891L (en)
PL (1) PL355852A1 (en)
WO (1) WO2000061616A1 (en)
ZA (1) ZA200107658B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291735B2 (en) 2012-03-06 2022-04-05 Life Science Inkubator Betriebs Gmbh & Co. Kg Drug delivery system based on JCV-VLP

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916224C1 (en) * 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetic molecule for delivering active ingredient to cell, used e.g. to treat human immune deficiency virus infection, comprises the ingredient linked to VP2 or 3 peptide from polyoma virus
GB2357084A (en) * 1999-12-06 2001-06-13 Amersham Pharm Biotech Uk Ltd A hydrophobic carrier peptide
DE10306789A1 (en) * 2003-02-18 2004-08-26 Responsif Gmbh Composition for administration to living organisms, useful for labeling treated organisms, comprises active agent and a protein complex comprising viral capsomers
US20090062237A1 (en) * 2007-06-15 2009-03-05 Mayo Foundation For Medical Education And Research Evaluating immune competence
CN113278634B (en) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 Novel vaccine for preventing and treating merkel cell carcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950599A (en) * 1987-01-29 1990-08-21 Wolf Bertling Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5858648A (en) * 1996-11-04 1999-01-12 Sienna Biotech, Inc. Assays using reference microparticles
US6165772A (en) * 1996-05-10 2000-12-26 Bertling; Wolf Vehicle for the transport of molecular substances
US7011968B1 (en) * 1999-04-10 2006-03-14 November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319101C (en) 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ES2123062T3 (en) * 1992-08-21 1999-01-01 Biogen Inc TRANSPORTATION POLYPEPTIDES DERIVED FROM TAT PROTEIN.
DE4335025A1 (en) 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytically active particles
DE19543553B4 (en) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP antigens of the JC virus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950599A (en) * 1987-01-29 1990-08-21 Wolf Bertling Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US6165772A (en) * 1996-05-10 2000-12-26 Bertling; Wolf Vehicle for the transport of molecular substances
US5858648A (en) * 1996-11-04 1999-01-12 Sienna Biotech, Inc. Assays using reference microparticles
US7011968B1 (en) * 1999-04-10 2006-03-14 November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291735B2 (en) 2012-03-06 2022-04-05 Life Science Inkubator Betriebs Gmbh & Co. Kg Drug delivery system based on JCV-VLP

Also Published As

Publication number Publication date
AU4285000A (en) 2000-11-14
EP1586582A1 (en) 2005-10-19
HUP0200679A2 (en) 2002-06-29
JP2002544122A (en) 2002-12-24
WO2000061616A1 (en) 2000-10-19
US7011968B1 (en) 2006-03-14
PL355852A1 (en) 2004-05-31
KR20020007361A (en) 2002-01-26
ATE303401T1 (en) 2005-09-15
IL145403A0 (en) 2002-06-30
EP1173475B1 (en) 2005-08-31
DE19916224C1 (en) 2000-06-21
BR0011178A (en) 2002-05-21
DE50011068D1 (en) 2005-10-06
EP1173475A1 (en) 2002-01-23
ZA200107658B (en) 2002-07-22
CZ20013621A3 (en) 2002-05-15
AU768669B2 (en) 2003-12-18
MXPA01010189A (en) 2003-07-21
EA200101066A1 (en) 2002-04-25
KR100627935B1 (en) 2006-09-22
DE10080849D2 (en) 2002-06-27
CA2364536A1 (en) 2000-10-19
EA006631B1 (en) 2006-02-24
NO20014891L (en) 2001-11-07
NO20014891D0 (en) 2001-10-08
CN1346366A (en) 2002-04-24

Similar Documents

Publication Publication Date Title
KR102397271B1 (en) Method for preparing amg 416
JP2594259B2 (en) Membrane anchor / active compound conjugate and method for producing the same
DEFOORT et al. A rational design of synthetic peptide vaccine with a built‐in adjuvant: A modular approach for unambiguity
US20070009921A1 (en) Fragments of virus protein 2 or 3 of polyoma virus as vehicles for active substances
JP2000512633A (en) Cyclic polypeptides containing thioether bonds and methods for their preparation
KR20100102652A (en) Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP0339695A2 (en) A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
Tuchscherer et al. The TASP concept: mimetics of peptide ligands, protein surfaces and folding units
WO2021167107A1 (en) Human transferrin receptor binding peptide
Lee et al. Nanoglue: an alternative way to display cell-internalizing peptide at the spikes of hepatitis B virus core nanoparticles for cell-targeting delivery
JP5785177B2 (en) Native ligation of polypeptides
EP1704167B1 (en) A method to make a peptide-carrier conjugate with a high immunogenicity
JP2022514411A (en) Lipopeptide building blocks and synthetic virus-like particles
CA1333563C (en) Synthetic vaccine against foot and mouth disease and a process for the preparation thereof
GB2282813A (en) Annular antigen scaffolds comprising thioether linkages
JP4927746B2 (en) Peptide cyclization on resin
CN109311910B (en) Tacrolimus conjugates, compositions thereof, and uses thereof
WO2020171028A1 (en) Hemagglutinin-binding peptide
Paradís Bas Development of New Tools for the Synthesis of" difficult Peptides"
Kinzel et al. Synthesis of a functionalized high affinity mannose receptor ligand and its application in the construction of peptide‐, polyamide‐and PNA‐conjugates
CN117320743A (en) Peptide antigen carrier proteins
GB2282812A (en) Cytotoxic/receptor ligand conjugates linked via lysine radicals
WO2021260176A1 (en) Synthetic epitopes of betacoronaviruses
CN110785182A (en) Silavidin (SILAFFIN) silica particle adjuvants
Paradís Bas Development of New Tools for the Synthesis of

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION